<?xml version="1.0" encoding="UTF-8"?>
<p id="p0060">Hydroxychloroquine is also proposed to control the cytokine storm that occurs in critically ill late phase SARS-CoV-2 infected patients.
 <xref rid="bib41" ref-type="bibr">
  <sup>41</sup>
 </xref> Hydroxychloroquine is significantly more potent than chloroquine 
 <italic>in vitro</italic> (EC
 <sub>50</sub> values: 0.72 and 5.47 μM, respectively) and has lower potential for drug–drug interactions than chloroquine. Pharmacokinetic models demonstrate that hydroxychloroquine sulfate is significant superior (5 days in advance) to chloroquine phosphate in inhibiting SARS-CoV-2 
 <italic>in vitro</italic>.
 <xref rid="bib41" ref-type="bibr">
  <sup>41</sup>
 </xref> The Taiwan CDC declared hydroxychloroquine as an important anti-SARS-CoV-2 agent on 26 March, 2020. Of note, patients with retinopathy, deficiency of glucose-6-phosphatase, QTc prolongation in electrocardiograms, history of allergy to hydroxychloroquine or who are pregnant or breastfeeding are contraindicated for receiving hydroxychloroquine therapy.
 <xref rid="bib42" ref-type="bibr">
  <sup>42</sup>
 </xref>
</p>
